A systematic review of the cost effectiveness of herpes zoster vaccination

PharmacoEconomics

Volumn 31, Issue 2, 2013, Pages 125-136

  Szucs, Thomas D ^a   Pfeil, Alena M ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

COST; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; VACCINATION;

AGE FACTORS; AGED; COST-BENEFIT ANALYSIS; DRUG COSTS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; NEURALGIA, POSTHERPETIC; QUALITY-ADJUSTED LIFE YEARS; REIMBURSEMENT MECHANISMS; VACCINATION;

EID: 84876225349     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-012-0020-7     Document Type: Review

References (41)

1. Bennett GJ, Watson CPN. Herpes zoster and post-herpetic neuralgia: past, present, and future. Pain Res Manage. 2009;14(4):275-82.
2. Wilson JF. Herpes zoster. Ann Intern Med. 2011;154(5):3-15.
3. Benbernou A, Drolet M, Levin MJ, et al. Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. Eur J Pain. 2011;15(10):1100-6.
4. Boivin G, Jovey R, Elliott CT, et al. Management and prevention of herpes zoster: a Canadian perspective. Can J Infect Dis Med Microbiol. 2010;21(1):45-52.
5. Drolet M, Brisson M, Levin MF, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010;26(8):656-66.
6. Chiappe SG, Sarazin M, Turbelin C, et al. Herpes zoster: burden of disease in France. Vaccine. 2010;28(50):7933-8.
7. Gershon AA, Gershon MD, Breuer J, et al. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 2010;48(Suppl. 1):2-7.
8. Gialloreti LE, Merito M, Pezzotti P, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10:230.
9. Ultsch B, Siedler A, Rieck T, et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.
10. Hurley LP, Harpaz R, Daley MF, et al. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine. J Infect Dis. 2008;197(Suppl. 2):216-23.
11. Lu P, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med. 2011;40(2):1-6.
12. Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305(2):160-6.
13. Hata A, Kuniyoshi M, Ohkusa Y. Risk of herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39(6):537-44.
14. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996;67(2-3):241-51.
15. Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23(6):490-6.
16. Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182(16):1731-6.
17. Mick G, Gallais JL, Simon F, et al. Burden of herpes zoster and post-herpetic neuralgia: incidence, proportion, and associated costs in the French population aged 50 or over [in French]. Rev Epidemiol Sante Publique. 2010;58(6):393-401.
18. Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics. 2003;21(1):13-38.
19. Centers for Disease Control and Prevention. Childhood immunization schedule, 2011. Atlanta: CDC; 2011. http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm6005a6.htm. Accessed 1 Sept 2011.
20. Centers for Disease Control and Prevention. Adult immunization schedule, 2011. Atlanta: CDC. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6004a10.htm. Accessed 1 Sept 2011.
21. ®): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010;27(2):159-76.
22. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-84.
23. Levin MJ, Gershon AA, Dworkin RH, et al. Prevention strategies for herpes zoster and post-herpetic neuralgia. J Clin Virol. 2010;48(Suppl. 1):14-9.
24. Oxman MN, Levin MJ, et al. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis. 2008;197(Suppl. 2):228-36.
25. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275-83.
26. Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53-61.
27. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19(23-24):3076-90.
28. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145(5):317-25.
29. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25(49):8326-37.
30. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44(10):1280-8.
31. Brisson M, Pellissier JM, Camden S, et al. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008;4(3):238-45.
32. Najafzadeh M, Marra CA, Galanis E, et al. Cost-effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009;27(12):991-1004.
33. van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454-67.
34. Annemans L, Bresse X, Gobbo C, et al. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010;13(3):537-51.
35. Moore L, Remy V, Martin M, et al. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc. 2010;8:7.
36. van Lier A, van Hoek AJ, Opstelten W, et al. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010;10:237.
37. van Wijck AJ, Opstelten W, Moons KG, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet. 2006;367:219-24.
38. Szucs TD, Kressig RW, Papageorgiou M, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011;7(7):749-56.
39. Michel JP, Kempf W. Data collection related to the management of herpes zoster (HZ) and post-herpetic neuralgia (PHN) and demographic parameters in Switzerland 2007 [unpublished].
40. Wasem J, Lang K, Papageorgiou M, et al. Health economic evaluation of a new vaccine for the prevention of herpes zoster and post-herpetic neuralgia in adults a German analysis [abstract no. PIH22]. Value Health. 2009;12(7):A294.
41. Ollendorf PA, Pearson SD. An integrated evidence rating to frame comparative effectiveness assessments for decision makers. Med Care. 2010;48(6 Suppl.):145S-52S.